26 December 2023 - The anticipated timeline for approval in Canada is approximately 12 months depending on review cycles and information requests by Health Canada.

Scilex today announced that it has filed a new drug submission to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of Elyxyb for acute treatment of migraine with or without aura in Canada.

Read Scilex press release